Kyverna Therapeutics (KYTX) vs SL Science (SLBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kyverna Therapeutics (KYTX) has outperformed SL Science (SLBT) over the past year, losing 39.9% versus a loss of 94.8%. SL Science is the larger company by market cap ($308.4 million vs $269.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYTX | SLBT |
|---|---|---|
| Share price | $4.26 | $0.55 |
| Market cap | $269.33M | $308.42M |
| 1-day change | -2.52% | -3.36% |
| YTD return | -54.68% | -94.78% |
| 1-year return | -39.92% | -94.76% |
| EPS (TTM) | $-2.75 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-161.31M | — |
| 52-week high | $13.67 | $14.50 |
| 52-week low | $4.18 | $0.51 |
| Distance from 52-week high | -68.84% | -96.21% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +613.62% | — |
| Average volume | 867.28K | 67.66K |
| Shares outstanding | 63.22M | 560.76M |
| Employees | 172 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYTX has outperformed SLBT by 54.8 percentage points over the past year.
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees
About SL Science
SLBT stock →SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
KYTX vs SLBT FAQ
Which is bigger, Kyverna Therapeutics or SL Science?
SL Science (SLBT) is larger, with a market capitalization of $308.42M compared with $269.33M for Kyverna Therapeutics (KYTX).
Which stock has performed better over the past year, KYTX or SLBT?
KYTX returned -39.92% over the past 12 months, compared with -94.76% for SLBT (price return, excluding dividends). Past performance does not predict future results.
Are Kyverna Therapeutics and SL Science in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.